105 results
8-K
EX-1
HRTX
Heron Therapeutics Inc
8 Aug 06
Results of Operations and Financial Condition
12:00am
and qualitative market assessment confirms
significant potential for APF530 at targeted profile.
Cash, cash equivalents and marketable securities … granisetron
formulated with the Company's proprietary Biochronomer(TM) drug
delivery system.
Market Assessment
- -----------------
A qualitative
8-K/A
EX-99.1
HRTX
Heron Therapeutics Inc
25 Jun 18
Other Events
4:01pm
(p=0.0325).
With the more conservative assessment of pain with activity, theHTX-011 combination andHTX-011 alone resulted in reductions of 16% and 12 … ).
With the more conservative assessment of pain with activity,HTX-011 400 mg instillation andHTX-011 400 mg nerve block resulted in reductions of 24
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
7 Nov 06
Results of Operations and Financial Condition
12:00am
hours) and delayed onset
(4-5 days) CINV in patients receiving either moderately or highly
emetogenic chemotherapy.
Market Assessment …
- -----------------
A qualitative and quantitative market assessment conducted by an
independent research company has confirmed the significance of the
market potential
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
21 Jun 18
Regulation FD Disclosure
8:11am
(p=0.0325).
With the more conservative assessment of pain with activity, theHTX-011 combination andHTX-011 alone resulted in reductions of 16% and 12 … ).
With the more conservative assessment of pain with activity,HTX-011 400 mg instillation andHTX-011 400 mg nerve block resulted in reductions of 24
S-8
EX-23.1
HRTX
Heron Therapeutics Inc
16 Aug 05
Registration of securities for employees
12:00am
Annual Report (Form 10-K) for the year ended December 31,
2004, and A.P. Pharma, Inc. management's assessment of the
effectiveness of internal control over
8-K
EX-99.3
lqfxk8qq387
21 Jun 18
Regulation FD Disclosure
8:11am
8-K/A
EX-99.3
hzv6jaggo6
25 Jun 18
Other Events
4:01pm
8-K
EX-99.1
lu23 1mork6r1d
14 May 19
Heron Therapeutics Presents New Results from Real-world Study Showing
8:35am
8-K
EX-99.1
tnjjockb
8 May 07
A.p. Pharma Reports Results for the First Quarter 2007; Updates Progress of APF530 Program
12:00am
424B3
o0jzx4kn0ba90zfrper
8 Nov 11
Prospectus supplement
12:00am
424B3
nr1j5qmj rb
8 Nov 11
Prospectus supplement
12:00am
424B3
n9e91f2o87
9 Aug 12
Prospectus supplement
12:00am
424B3
iip jgzyaftfsxn6n
9 Aug 12
Prospectus supplement
12:00am